---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-017063"
form_type: "8-K"
ticker: "ETON"
cik: "0001710340"
company_name: "Eton Pharmaceuticals, Inc."
filed_at: "2026-05-14T20:16:28+00:00"
generated_at: "2026-05-14T20:49:04.039885+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Eton Pharma Q1 product sales $24.3M (+73% YoY); raises FY2026 guidance to >$120M

## Summary
- Q1 product sales $24.3M (+73% YoY); GAAP diluted EPS $0.05, non-GAAP diluted EPS $0.14, Adj. EBITDA $5.7M (24% margin)
- Raises full-year 2026 revenue guidance to >$120M from prior $110M; expects ≥30% Adj. EBITDA margin
- Launched DESMODA (FDA-approved oral desmopressin solution); acquired and relaunched HEMANGEOL on May 1
- Initiated ET-700 clinical study (extended-release zinc acetate for Wilson disease); FDA cleared INCRELEX label harmonization study
- Net income of $1.6M vs net loss of $1.6M in Q1 2025; cash $19.7M after $14M HEMANGEOL acquisition

## SEC filing metadata
- accession: 0001437749-26-017063
- form_type: 8-K
- ticker: ETON
- cik: 0001710340
- company_name: Eton Pharmaceuticals, Inc.
- filed_at: 2026-05-14T20:16:28+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1710340/000143774926017063/0001437749-26-017063-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1710340/000143774926017063/eton20260322_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-017063
- JSON: https://secwatch.observer/filing/0001437749-26-017063.json
- Plain text: https://secwatch.observer/filing/0001437749-26-017063.txt

## Key facts
- Earnings Releases
  Eton Pharmaceuticals, Inc. reported the quarter ended March 31, 2026 results: revenue $24.3 million, EPS $0.05. Guidance raised.
  - Period: the quarter ended March 31, 2026
  - Revenue: $24.3 million
  - EPS: $0.05
  - Guidance: raised
  - Result: reported results
  source text: Q1 2026 product sales of $24.3 million, representing 73% growth over Q1 2025 ● Raising full year revenue guidance - now expect 2026 revenue to exceed $120 million, up from previous guidance of $110 million ● Q1 2026 fully diluted GAAP EPS of $0.05
  evidence_url: https://www.sec.gov/Archives/edgar/data/1710340/000143774926017063/0001437749-26-017063-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.